SAB BIOTHERAPEUTICS, INC. Increase (Decrease) in Accrued Taxes Payable
SAB BIOTHERAPEUTICS, INC. (SABS) reported Increase (Decrease) in Accrued Taxes Payable of $0 for the 9-month period ending 2022-09-30, per its 10-K filed 2023-04-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedTaxesPayable · last filed 2023-04-14
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accrued taxes payable for the quarter ending 2022-09-30 was $0.00.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accrued taxes payable for the quarter ending 2022-06-30 was -$92.28K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accrued taxes payable for the quarter ending 2022-03-31 was $92.28K.
| Period end | Increase (Decrease) in Accrued Taxes Payable 3 month | Increase (Decrease) in Accrued Taxes Payable 6 month | Increase (Decrease) in Accrued Taxes Payable 9 month |
|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-K 9 month − 10-K 6 month · filed 2023-04-14 | -$92.28K derived: sum of 2 quarters · filed 2023-04-14 | $0.00 10-K · filed 2023-04-14 |
| 2022-06-30 | -$92.28K derived: 10-K 6 month − 10-K 3 month · filed 2023-04-14 | $0.00 10-K · filed 2023-04-14 | |
| 2022-03-31 | $92.28K 10-K · filed 2023-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |